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Abstract
Background: To characterize the utilization of Traditional Chinese Medicine (TCM) among patients with hepatitis C (HC).
Methods: This study examined datasets from the National Health Insurance Research Database in Taiwan. One cohort,
including one million patients randomly sampled from the beneficiaries of the National Health Insurance Programme
from January 1 to December 31 in 2010, was chosen for this analysis. People who had at least three outpatient or
inpatient records and had been diagnosed with hepatitis C virus infection from 2000 to 2010 were defined as patients
with HC. Patients with HC who had at least one TCM outpatient clinical record from 2000 to 2010 were defined as TCM
users (N = 5,691), whereas patients with no TCM outpatient records were defined as non-TCM users (N = 2,876). The
demographic data, treatment modalities and disease distributions of TCM users were analysed.
Results: Overall, 66.4 % of the patients with HC had used TCM from 2000 to 2010. Of the TCM users, 54.1 % were
female. The utilization rate of TCM increased with age and peaked in the age group of those 40 − 64 years old.
Herbal remedies (52.4 %) were the most commonly used agents, followed by combination therapy (46.4 %) and
acupuncture alone (1.2 %). Patients who had more extrahepatic diseases and were taking more antiviral agents
tended to visit TCM clinics. Jia-Wei-Xiao-Yao-San and Dan-Shen (Salvia miltiorrhiza) were the most commonly
used formula and single herb, with 88,124 person-days and 59,252 person-days, respectively.
Conclusions: Our nationwide population-based study revealed a high prevalence and specific usage patterns of
TCM in patients with HC in Taiwan.
Keywords: Complementary and alternative medicine, Hepatitis C, National Health Insurance Research Database,
Traditional Chinese medicine
Background
The use of complementary and alternative medicine
(CAM) is expanding throughout the world [1, 2]. Ac-
cording to the World Health Organization (W.H.O.),
CAM includes Ayurveda, traditional Chinese medicine
(TCM) and Unani medicine. TCM is widely used in East
Asia [3]. Of the twenty-three million people in Taiwan,
29.1 % used TCM to treat disease in 2014, whereas up
to three-fourths of South Korean adults utilized TCM to
treat a specific disease [4].
Hepatitis C virus (HCV), which affects 180 million
people globally, is a leading cause of chronic hepatitis,
cirrhosis, and hepatocellular carcinoma [5]. Conven-
tional anti-viral therapy consisting of pegylated inter-
feron and ribavirin is associated with many intolerable
side effects and low response rates in some patients’ ge-
notypes [6]. Therefore, patients often seek for alternative
treatments to promote healing and obtain support [7].
However, the communication regarding CAM between
patients and physicians is relatively poor [8, 9], and the
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non-disclosure rate is higher than 70 %. Many physicians
feel uncomfortable discussing CAM because of their
limited knowledge of the subject. Patients avoid discuss-
ing CAM with their doctors because they fear receiving
a negative response [10]. To provide holistic care to pa-
tients with hepatitis C (HC), physicians should under-
stand the approaches used by patients for symptom
relief and health maintenance. In the United States, 80 %
of patients with HC used CAM according to a report
from 2007 [11]. Compared with patients with fatty liver
disease, patients with HC were approximately 3 times
more likely to use CAM [12]. Because there has been
growing interest in using CAM to treat populations with
HC worldwide [13], information about CAM and com-
prehensive studies on its prevalence, usage patterns, effi-
cacy and safety are important.
TCM, defined by the National Centre for Complemen-
tary and Integrative Health (NCCIH, U.S.A.) as an entire
medical system of CAM, is a well-established medical
system that has been used for more than 2,000 years.
TCM is commonly used by the Chinese population, as
well as by those in many other countries [14], including
Taiwan [15]. In Taiwan, TCM has been reimbursed by
the National Health Insurance (NHI) programme since
1996. As of 2014, 99.9 % of Taiwan’s population were en-
rolled in the NHI. All of the claims data have been col-
lected in the National Health Insurance Research
Database (NHIRD). According to the NHI programme
guidelines, TCMs are only provided for outpatient care
including Chinese herbal prescriptions, acupuncture,
and traumatology manipulative therapy. The utilization
prevalence of TCM in Taiwan ranges from 19.8 % to
77.9 % for many diseases including colon cancer [16],
liver cancer [17], osteoporosis [18], and type II diabetes
mellitus [19]. However, the utilization and prescription
patterns of TCM in HC are lacking.
To characterize the utilization patterns and trends in
TCM usage among patients with HC, we analysed a co-
hort of one million randomly sampled beneficiaries from
the NHIRD in 2010. The results of this study should




As previously described in detail [20], all TCM services cov-
ered under the NHI are provided only in ambulatory
clinics. In Taiwan, TCM physicians (those who have re-
ceived a series of training in Chinese or both Chinese and
Western medicine, all of whom must pass national licens-
ing examinations and complete residency training pro-
grammes in hospitals) are requested to make diagnoses
based on the International Classification of Disease, 9th
Revision, Clinical Modification (ICD-9-CM) coding [16].
This study chose one cohort for the analysis, which in-
cluded one million patients randomly sampled from the
beneficiaries of the NHI programme in 2010. The NHIRD
contains information on the medical care facilities, phys-
ician specialties, and patients’ gender, dates of birth, dates
of visit, masked identification numbers, prescriptions, man-
agement and diagnosis codes in the ICD-9-CM. A max-
imum of three diagnostic codes were listed in the NHIRD,
and all the diagnoses were analysed in our study. This study
was approved by the Research Ethics Committee of the
Taipei City Hospital (TCHIRB-10406112-E).
Study subjects
The study subjects were selected from a random sample
of one million individuals in 2010 in the following man-
ner (Fig. 1): People who had at least three outpatient or
inpatient records and had been diagnosed with HCV
from January 1, 2000, to December 31, 2010, were de-
fined as patients with HC (ICD-9-CM codes 07054,
0707, 07041, 07044, 07051, V0262). Based on this cri-
teria, there were 8,567 patients older than 18 years old
with a new HCV infection diagnosed starting from the
index date of January 1, 2000. Patients with HC who had
at least one TCM clinical record from 2000 to 2010 were
defined as TCM users (N = 5,691), whereas those who
had no TCM records during the same period were de-
fined as non-TCM users (N = 2,876). All study subjects
were followed until December 31, 2011.
Fig. 1 Flow chart of subjects in the one million randomly selected
sample from the National Health Insurance Research Database
(NHIRD) from 2000 to 2010 in Taiwan
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Statistical analysis
The data were analysed using SAS software program,
version 9.4 (SAS Institute Inc., Cary, NC, U.S.A.). A
univariate analysis was used to compare the TCM
users with the non-TCM users. Chi-squared test was
performed to assess the relationships between the cat-
egorical variables and to examine the differences be-
tween TCM users and non-users. Person-years for the
follow-up period were calculated for each patient until
diagnosis of multisite diseases, censor or December
31, 2011. The person-years and overlapping confi-
dence interval (CI) were calculated to assess incidence
density rates. To compare the study cohort to the
comparison cohort rate, ratios were examined using a
Poisson regression model. Moreover, we estimated the
adjusted hazard ratios using Cox proportional hazards
model. A P value <0.05 was considered statistically
significant.
Results
Demographic characteristics of the TCM users with HC
Of the patients with HC, 66.4 % (N = 5,691) had previ-
ously used TCM (Table 1). In the TCM users, 54.1 %
were female, and this differed from the percentage in
non-TCM users, which was only 39.9 %. In both TCM
users and non-users, the highest proportion of pa-
tients was in the age group from 40 to 64 years old.
Regarding the comorbidities of patients with HC, the
incidence of most diseases, including osteoarthritis,
sicca syndrome, thyroid disorders, chronic obstructive
pulmonary disease, and hepatitis B, were higher in
TCM users, except for diabetes mellitus, which had a
similar incidence in both groups. In contrast, the inci-
dence of hepatocellular carcinoma, liver cirrhosis, and
alcohol-related diseases were higher in non-TCM
users.
To examine the frequency of utilization of Western
medicine, we analysed the claims data according to
the antiviral or hepatoprotective agents used
(Table 1). A higher percentage of TCM users than
non-TCM users had ever used these agents to con-
trol hepatitis C (all p-values < 0.001). TCM users
tended to use interferon-alpha, ribavirin, and sily-
marin to treat HCV (17.1 %, 17.1 %, and 73.9 %,
respectively).
With regard to TCM outpatient visits (Table 2),
herbal remedies (52.4 %) were the most commonly
used therapeutic approach, followed by combined
therapy (46.4 %) and acupuncture alone (1.12 %). As
for the frequency of visits, the majority of patients vis-
ited TCM clinics fewer than three times (74.01 %).
Only 16.64 % of the patients visited TCM clinics more
than six times.
Table 1 Demographic characteristics of the patients with
hepatitis C in Taiwan in 2000-2011





n % n %
Sex <0.0001
Female 1148 39.92 3081 54.14
Male 1728 60.08 2610 45.86
Age at baseline <0.0001
18−39 364 12.66 945 16.61
40−64 1451 50.45 3395 59.66
≥ 65 1061 36.89 1351 23.74
Mean (STD) 58.34 14.85 53.92 13.97
Urbanizationa <0.0001
1 (highest) 574 19.96 1215 21.35
2 731 25.42 1652 29.03
3 447 15.54 939 16.50
4+ (lowest) 1124 39.08 1885 33.12
Co-morbidity
Hepatitis B 570 19.82 1356 23.83 <0.0001
Liver cirrhosis 989 34.39 1618 28.43 <0.0001
hepatocellular carcinoma 535 18.60 898 15.78 0.0009
Alcohol-related disease 294 10.22 477 8.38 0.0049
Chronic obstructive pulmonary
disease
508 17.66 1402 24.64 <0.0001
Diabetes Mellitus 1046 36.37 2143 37.66 0.2449
Thyroid disorders 145 5.04 631 11.09 <0.0001
Rheumatoid arthritis 89 3.09 400 7.03 <0.0001
Osteoarthritis 953 33.14 2922 51.34 <0.0001
Depression 174 6.05 650 11.42 <0.0001
Sicca syndrome 78 2.71 423 7.43 <0.0001
Charlson comorbidity index score <0.0001
0 1203 41.83 3024 53.14
1 377 13.11 769 13.51
More than 2 1296 45.06 1898 33.35
Anti-viral or hepatoprotective agents
Interferon alfa 392 13.63 974 17.11 <0.0001
Ribavirin 391 13.60 973 17.10 <0.0001
Silymarin 1916 66.62 4204 73.87 <0.0001
Times of visits (mean, SD) 15.61 17.18 21.23 23.18 <0.0001
aThe townships within which subjects registered for insurance were grouped
into 4 levels of urbanization, based on a score calculated by incorporating
variables indicating population density (people/km2), and population ratio of
different educational levels, population ratio of elderly, population ratio of
people of agriculture workers and the number of physicians per
100,000 people
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The prevalence of hepatitis B, liver cirrhosis, alcohol-
related disease, chronic obstructive pulmonary disease
and diabetes mellitus was lower in TCM users than
non-TCM users in Taiwanese HC patients
After adjusting for the frequency of outpatient and in-
patient visits, Charlson comorbidity index score, and
type of service used - only herbal medicine, only acu-
puncture or a combination - we calculated the disease
hazard ratio (HR) of TCM users versus non-TCM users
to compare the prevalence of comorbidities between
them. We found that TCM users tended to have certain
comorbidities less frequently than non-TCM users
(Table 3). TCM users had a 0.55 times lower HR of hav-
ing hepatitis B than non-TCM users (95 % confidence
interval 0.46 − 0.66). Patients who received TCM treat-
ment also had a lower ratio for liver cirrhosis (HR 0.42,
with 95 % CI 0.37 − 0.48) and alcohol-related disease
(HR: 0.31 for the 40−64 age group and 0.41 overall). The
prevalence of chronic obstructive pulmonary disease was
also lower in the TCM users (HR: 0.59 overall). Diabetes
mellitus also showed a lower incidence in TCM users
than non-TCM users overall and in each age group (HR:
0.48, 0.40, 0.46 and 0.64 for the sample overall and for
the <40, 40–64, and >60 age groups, respectively). How-
ever, after adjusting for times of visit, Charlson comor-
bidity index score, and type of TCM service used, the
hazard ratio of comorbidities such as sicca syndrome,
rheumatoid arthritis, depression, and thyroid disorders
was less than 1, with no significance.
Frequency distribution of disease categories in TCM
versus non-TCM visits
To delineate the frequency distributions of the disease
categories (as the reasons for visits) for the TCM and
non-TCM visits, we analysed the ICD-9-CM codes from
the claims data (Table 4). There was a significant differ-
ence in the disease distributions between the TCM and
non-TCM users (P < 0.0001). Among all of the visits, in-
fectious diseases (99.68 %), which included viral hepa-
titis, were the most common reasons that TCM users
visited TCM clinics. Digestive system diseases (99.61 %),
which included chronic liver disease, were the second
most common reason that TCM users visited TCM
clinics. Symptoms/signs and ill-defined conditions
(97.96 %) and respiratory system diseases (97.93 %)
accounted for the third and fourth disease categories, re-
spectively, followed by diseases of the musculoskeletal
system and connective tissue (93.89 %) and injuries
(90.77 %). For non-TCM users, infectious diseases
(99.51 %) were the most common reason for visiting
Western medical clinics, followed by digestive system
diseases (97.25 %) and symptoms/signs and ill-defined
conditions (89.33 %). When TCM users required med-
ical services, their utilization patterns were similar to
those of non-TCM users.
The most commonly used TCM prescriptions
To comprehensively understand the TCM prescriptions, in-
cluding the formulas and herbs, we analysed the claims
data, and the results are shown in Table 5. Of the 10 most
common formulas of TCM used by patients with HC, Jia-
wei-xiao-yao-san (88,124 person-days) was the most com-
monly used. Xiao-chai-hu-tang (39,837 person-days) and
Long-dan-xie-gan-tang (36,293 person-days) accounted for
the second and third most commonly used formulas, re-
spectively. With regard to the single herbs used for TCM
by patients with HC, Dan-shen (59,252 person-days) was
the most common. Yan-hu-suo (41,875 person-days) and
Huang-qin (35,273 person-days) were the second and third
most commonly used herbs, respectively.
Discussion
This research is the first large-scale study on the
utilization patterns of TCM by patients with HC and
was conducted by analysing claims data from TCM and
non-TCM clinic visits covered by the NHI in Taiwan. In
a previous study [21], Chen et al. investigated the fre-
quency and prescription patterns of Chinese herbal
medicine for chronic hepatitis, including viral hepatitis
and alcoholic hepatitis, and revealed the same three
most common herbal formulas as in our study and a
similar age group of patients, approximately in their 40s
to 50s, seeking TCM. However, this study focused only
on hepatitis C and demonstrated a different gender pre-
dominance and more details on comorbidities. Accord-
ing to Sievert’s review [22], the prevalence rate of
hepatitis C is as high as 4 %, but the diagnosis rate is
only 1.3 %, which is similar to our report. This discrep-
ancy may be due to the fact that only symptomatic pa-
tients with HC would visit the hospital and have
Table 2 Distribution of Chinese medicine according to type of Chinese Medicine treatment received in patients with hepatitis C,
stratified by number of outpatients visits
Number of TCM
visits (times/per year)
Only Chinese herbal remedies Only Acupuncture or traumatology Combination both treatment Total of TCM
(N = 5691)N = 2984 (52.43 %) N = 64 (1.12 %) N = 2643 (46.44 %)
1-3 2423 (81.20 %) 64 (100 %) 1725 (65.27 %) 4212 (74.01 %)
4-6 212 (7.10 %) 0 320 (12.11 %) 532 (9.35 %)
>6 349 (11.70 %) 0 598 (22.63 %) 947 (16.64 %)
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Table 3 Incidence rate ratio for common disease between non-TCM and TCM user in different age groups
Age groups (year-old) Non-TCM user TCM user IRR (95 % CI) Adjusted HRb
Disease (ICD-9-CM) N (%) Person-years IRa N (%) Person-years IRa (95 % CI)
Hepatitis B (70.2, 070.3, V02.61)
All 570(19.82) 13085 43.56 1356(23.83) 39350 34.46 0.79(0.72−0.87)*** 0.55(0.46−0.66)***
18−39 88(24.18) 1901 46.3 239(25.29) 7189 33.24 0.72(0.56−0.92)** 0.41(0.25−0.69)***
40−64 327(22.54) 6923 47.23 842(24.80) 23900 35.23 0.75(0.66−0.85)*** 0.48(0.37−0.6)***
≥ 65 155(14.61) 4261 36.37 275(20.36) 8260 33.29 0.92(0.75−1.11) 0.82(0.58−1.17)
Liver cirrhosis (571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 572.8, 573.0)
All 989(34.39) 13085 75.58 1618(28.43) 39350 41.12 0.54(0.50−0.59)*** 0.42(0.37−0.48)***
18−39 45(12.36) 1901 23.68 108(11.43) 7189 15.02 0.63(0.45−0.90)* 0.43(0.25−0.73)**
40−64 489(33.70) 6923 70.63 951(28.01) 23900 39.79 0.56(0.51−0.63)*** 0.39(0.33−0.46)***
≥ 65 455(42.88) 4261 106.77 559(41.38) 8260 67.67 0.63(0.56−0.72)*** 0.54(0.44−0.66)***
hepatocellular carcinoma (155)
All 535(18.60) 13085 40.89 898(15.78) 39350 22.82 0.56(0.50−0.62)*** 0.78(0.45−1.36)
18−39 6(1.65) 1901 3.16 33(3.49) 7189 4.59 1.45(0.61−3.47) 1.25(0.12−12.75)
40−64 242(16.68) 6923 34.96 514(15.14) 23900 21.51 0.62(0.53−0.72)*** 0.98(0.43−2.21)
≥ 65 287(27.05) 4261 67.35 351(25.98) 8260 42.49 0.63(0.54−0.74)*** 0.72(0.29−1.75)
Alcohol-related disease (291, 303.0, 303.9, 305.0, 571.0, 571.1, 571.3)
All 294(10.22) 13085 22.47 477(8.38) 39350 12.12 0.54(0.47−0.62)*** 0.41(0.32−0.51)***
18−39 65(17.86) 1901 34.2 124(13.12) 7189 17.25 0.50(0.37−0.68)*** 0.37(0.24−0.58)***
40−64 185(12.75) 6923 26.72 290(8.54) 23900 12.13 0.45(0.38−0.55)*** 0.31(0.23−0.42)***
≥ 65 44(4.15) 4261 10.33 63(4.66) 8260 7.63 0.74(0.50−1.09) 0.61(0.33−1.16)
Chronic obstructive pulmonary disease (491, 492)
All 508(17.66) 13085 38.82 1402(24.64) 39350 35.63 0.92(0.83−1.12) 0.59(0.50−0.70)***
18−39 27(7.42) 1901 14.21 120(12.70) 7189 16.69 1.18(0.77−1.78) 0.94(0.45−1.97)
40−64 198(13.65) 6923 28.6 786(23.15) 23900 32.89 1.15(0.98−1.34) 0.67(0.52−0.86)**
≥ 65 283(26.67) 4261 66.41 496(36.71) 8260 60.05 0.90(0.78−1.05) 0.69(0.53−0.89)**
Diabetes Mellitus (250)
All 1046(36.37) 13085 79.94 2143(37.66) 39350 54.46 0.68(0.63−0.73)*** 0.48(0.42−0.55)***
18−39 55(15.11) 1901 28.94 151(15.98) 7189 21 0.73(0.53−0.99)* 0.40(0.22−0.71)**
40−64 572(39.42) 6923 82.62 1358(40.00) 23900 56.82 0.69(0.62−0.76)*** 0.46(0.38−0.54)***
≥ 65 419(39.49) 4261 98.32 634(46.93) 8260 76.75 0.78(0.69−0.88)*** 0.64(0.51−0.8)***
Thyroid disease (240, 241, 242, 244)
All 145(5.04) 13085 11.08 631(11.09) 39350 16.04 1.44(1.21−1.73)*** 0.90(0.67−1.21)
18−39 21(5.77) 1901 11.05 105(11.11) 7189 14.6 1.32(0.83−2.11) 1.33(0.54−3.28)
40−64 79(5.44) 6923 11.41 418(12.31) 23900 17.49 1.53(1.21−1.95)*** 0.9(0.6−1.36)
≥ 65 45(4.24) 4261 10.56 108(7.99) 8260 13.07 1.24(0.87−1.75) 0.92(0.53−1.58)
Rheumatoid arthritis (714)
All 89(3.09) 13085 6.8 400(7.03) 39350 10.17 1.49(1.19−1.88)*** 1.18(0.82−1.69)
18−39 11(3.02) 1901 5.79 42(4.44) 7189 5.84 1.01(0.52−1.96) 0.88(0.28−2.78)
40−64 45(3.10) 6923 6.5 266(7.84) 23900 11.13 1.71(1.25−2.35)*** 1.38(0.81−2.36)
≥ 65 33(3.11) 4261 7.74 92(6.81) 8260 11.14 1.44(0.97−2.14) 1.24(0.69−2.22)
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Table 3 Incidence rate ratio for common disease between non-TCM and TCM user in different age groups (Continued)
Osteoarthritis (715)
All 953(33.14) 13085 72.83 2922(51.34) 39350 74.26 1.02(0.95−1.10) 0.75(0.66−0.86)***
18−39 46(12.64) 1901 24.2 215(22.75) 7189 29.91 1.24(0.90−1.70) 1.2(0.64−2.27)
40−64 427(29.43) 6923 61.68 1777(52.34) 23900 74.35 1.21(1.08−1.34)*** 0.85(0.71−1.03)
≥ 65 480(45.24) 4261 112.64 930(68.84) 8260 112.59 1.00(0.90−1.12) 0.82(0.67−1)
Depression (296.2, 296.3, 296.5, 296.6, 305.8, 311, v790, 290.13)
All 174(6.05) 13085 13.3 650(11.42) 39350 16.52 1.24(1.05−1.47)* 0.78(0.61−1.01)
18−39 31(8.52) 1901 16.31 128(13.54) 7189 17.8 1.09(0.74−1.62) 0.76(0.42−1.38)
40−64 86(5.93) 6923 12.42 382(11.25) 23900 15.98 1.29(1.02−1.63)* 0.73(0.52−1.04)
≥ 65 57(5.37) 4261 13.38 140(10.36) 8260 16.95 1.27(0.93−1.72) 0.89(0.54−1.48)
Sicca syndrome (370.33, 710.2)
All 78(2.71) 13085 5.96 423(7.43) 39350 10.75 1.80(1.42−2.30)*** 1.27(0.86−1.89)
18−39 4(1.10) 1901 2.1 42(4.44) 7189 5.84 2.78(1.00−7.74) -
40−64 40(2.76) 6923 5.78 266(7.84) 23900 11.13 1.93(1.38−2.69)*** 1.14(0.67−1.94)
≥ 65 34(3.20) 4261 7.98 115(8.51) 8260 13.92 1.75(1.19−2.56)** 1.71(0.93−3.15)
aIR incidence rate, per 1000 person-years, IRR incidence rate ratio
*:<0.05; **:<0.01; *** p < 0.001
bHazard Ratio adjusted for times of outpatient and inpatient visit, Charlson comorbidity index score and type of service used - only herbal medicine, only
acupuncture and combination of them
Table 4 The distribution of TCM and non-TCM user by major disease categories /diagnosis in patients with hepatitis C
Disease (ICD-9-CM) Non-TCM user (N = 2876) TCM user (N = 5691) p value
n % n %
Infectious and parasitic disease (001−139) 2862 99.51 5673 99.68 0.2218
Neoplasms (140−239) 1289 44.82 3121 54.84 <0.0001
Malignant(140−208) 824 28.65 1491 26.20 0.0158
Benign (210−229) 597 20.76 2152 37.81 <0.0001
Endocrine, nutritional and metabolic disease and immunity
disorder (240−279)
1863 64.78 4133 72.62 <0.0001
Blood and blood-forming organs (280−289) 843 29.31 1876 32.96 0.0006
Mental disorder (290−319) 1206 41.93 3360 59.04 <0.0001
Nervous system (320−389) 2087 72.57 5120 89.97 <0.0001
Circulatory system (390−459) 2123 73.82 4410 77.49 0.0002
Respiratory system (460−519) 2548 88.60 5573 97.93 <0.0001
Digestive system (520−579) 2797 97.25 5669 99.61 <0.0001
Genitourinary system (580−629) 1760 61.20 4485 78.81 <0.0001
Complications of pregnancy, childbirth and the
puerperium (630−676)
19 0.66 178 3.13 <0.0001
Skin and subcutaneous tissue (680−709) 1958 68.08 4830 84.87 <0.0001
Musculoskeletal system and connective tissue (710−739) 2091 72.71 5343 93.89 <0.0001
Congenital anomalies (740−759) 126 4.38 511 8.98 <0.0001
Certain conditions originating in the perinatal period (760−779) 13 0.45 43 0.76 0.0997
Symptoms, signs and ill-defined conditions (780−799) 2569 89.33 5575 97.96 <0.0001
Injury and poisoning (800−999) 1997 69.44 5166 90.77 <0.0001
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Table 5 Most common Chinese herbs and formula prescribed for patients with hepatitis C
Prescription name
(in Chinese)











Yan-hu-suo Corydalis yanhusuo H & E: Activate blood, promote flow of qi, and
alleviate pain
Also used in peptic ulcer
41875 3 7.1
Huang-qin Scutellaria baicalensis Georgi H: Clear heat and drain fire
Anti-inflammation
35273 2.2 8.1
Yin-chen-hao Artemisia capillaris Thunb H: Excrete dampness and alleviate jaundice
Anti-fibrosis
33357 2.4 10.1
Da-huang Rheum officinale Baill E: Clear heat and drain fire
Anti-tumor
32110 1.1 7.9
Huang-qi Astragalus membranaceus H&E: Qi-tonifying/ restore energy
Anti-cancer
30086 2.1 8.8
Bei-mu Fritillariae thunbergii Bulbus E: Clear heat and resolve phlegm
Also used in peptic ulcer and asthma
29404 2.7 7.1
Ge-gen Pueraria thomsonii Benth E: Release exterior and cure heat
Also used in ischemic heart disease
29143 2 7.4
Ye-jiao-teng Polygonum multiflorum Thunb. E: Nourish heart and induce tranquilization
Also used in menopausal syndrome
28559 3.3 8.7
Hai-piao-xiao Sepiella maindronide Rochebrune E: Restrain acidity and alleviate pain 27940 2.5 8.4
Formulae Also used in peptic ulcer
Jia-wei-xiao-yao-san Glycyrrhiza uralensis Fisch. Angelica sinensis, Atractylodes
macrocephala, Bupleurum chinense, Gardenia jasminoides,
Mentha haplocalyx, Paeonia lactiflora, Paeonia suffruticosa,
Poria cocos, Zingiber officinale
H & E: Harmonize liver and release spleen;
Also used in thyroid disorders
88124 7.5 9.3
Xiao-chai-hu-tang Bupleurum chinense, Scutellaria baicalensis Georgi, Pinellia
ternata (Thunb.) Makino, Panax ginseng C.A. Mey,
Glycyrrhiza uralensis Fisch, Zingiber officinale, Zizyphus jujuba
H: Regulate exterior and interior Qi activity by
balancing between yin and yang;
Antihepatocarcinoma
39837 6.7 7.9
Long-dan-xie-gan-tang Gentiana scabra Bge, Scutellaria baicalensis Georgi, Gardenia
jasminoides Ellis, Alisma orientalis, Akebia quinata (Houtt.)
Decne., Plantago asiatica L., Angelica sinensis, Rehmannia
glutinosa (Gaert.) Libosch., Bupleurum chinense, Glycyrrhiza
uralensis Fisch.
H: Purge fire in the liver and gallbladder, clear




















Table 5 Most common Chinese herbs and formula prescribed for patients with hepatitis C (Continued)
Shu-jing-huo-xue-tang Angelica sinensis, Paeonia lactiflora Pall, Glycyrrhiza uralensis
Fisch, Rehmannia glutinosa (Gaert.) Libosch, Atractylodes
lancea, Achyranthes bidentata Blume, Citrus tangerina
pericarpium, Citrus reticulata Blanco, Prunus persica (L.)
Batsch, Clematis chinensis Osbeck, Ligusticum striatum
DC., Stephania tetrandra S. Moore, Notopterygium incisum,
Angelica dahurica (Fisch. ex Hoffm.) Benth, Gentiana scabra
Bge, Poria cocos, Zingiber officinale Rosc.,
E: Relax the channels and activate blood;
Also used in osteoarthritis and rheumatoid
arthritis
32646 10.3 6.9
Xiang-sha-liu-jun-zi-tang Aquilaria sinensis, Amomum villosum Lour, Citrus reticulata
Blanco, Pinellia ternata (Thunb.), Panax ginseng C.A. Mey,
Poria cocos, Atractylodes macrocephala Koidz., Glycyrrhiza
uralensis Fisch.
E: Tonify and replenish qi
Also used in functional dyspepsia and post-surgery
colon cancer patients
28381 7.1 8.3
Gan-lu-yin Rehmannia glutinosa, Asparagus cochinchinensis (Lour.)
Merr., Liriope spicata (Thunb.) Lour., Dendrobium nobile
Lindl., Artemisia capillaris Thunb, Scutellaria baicalensis
Georgi, Citrus aurantium L., Eriobotrya japonica (Thunb.)
Lindl., Glycyrrhiza uralensis Fisch,
H& E: Clear heat and nourish yin;
Also used in Sicca syndrome
27563 6.1 7.6
Xue-fu-zhu-yu-tang Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong hort,
Paeonia anomala L., Prunus persica (L.), Batsch, Carthamus
tinctorius L., Rehmannia glutinosa (Gaert.) Libosch, Citrus
aurantium L., Bupleurum chinense DC., Glycyrrhiza uralensis
Fisch, Platycodon grandiflorum (Jacq.) A. DC., Achyranthes
bidentata Blume,
E: Promote blood circulation to remove blood stasis
Also used in ischemic heart disease and hyperlipidemia.
27493 6.6 8.1
Du-huo-ji-sheng-tang Angelica pubescens Maxim, Taxillus chinensis (DC.) Danser,
Eucommia ulmoides Oliver, Achyranthes bidentata Blume,
Asarum heterotropoides F. Schmidt, Gentiana macrophylla
Pall, Poria cocos, Cinnamomum cassia Presl, Saposhnikovia
divaricata (Turcz.) Schischk, Ligusticum striatum DC., Panax
ginseng C.A. Mey., Glycyrrhiza uralensis Fisch, Angelica sinensis,
Paeonia lactiflora Pall.
E: Reinforce the liver and kidney and tonify qi and
blood;
Also used in fracture, osteoarthritis and rheumatoid
arthritis
27388 11.1 8.2
Suan- zao-ren-tang Ligusticum striatum DC., Ziziphus jujuba Mill. Poria cocos,
Glycyrrhiza uralensis Fisch, Anemarrhena asphodeloides Bge
E: Nourish blood to tranquilize the mind;
Also used in insomnia and depression
26417 8 7.5
Ping-wei-san Citrus reticulata Blanco, Atractylodes lancea (Thunb.),
Magnolia officinalis Rehd, Glycyrrhiza uralensis Fisch
E: Activate the flow of Qi and regulate the stomach
Also used in leukemia patients
26083 7.2 7.6


















diagnostic records. Other HCV carriers without medical
seeking behaviour would not be recorded in the national
health insurance database.
Of the patients with HC, 66.4 % had previously used
TCM. The acceptance of TCM among patients with
HC is much greater in Taiwan than in other countries
[11, 12]. In addition, approximately 16 % of the patients
visited TCM clinics more than six times per year
(Table 2). This high visiting frequency might be ex-
plained by the fact that many of these patients had
chronic illnesses that required long-term care and
treatment. Moreover, unlike the predisposition towards
acupuncture in Europe [23], herbal remedies have been
widely used in Taiwanese patients with HC (52.4 %).
People in Taiwan believe that TCM can adjust the con-
stitution of the human body, allowing small doses of
herbal remedies to remain safe and suitable for long-
term use [24]. Furthermore, the insurance coverage for
TCM treatments might play a significant role in the
high TCM usage in Taiwan [25]. As for receiving the
current standard treatment, the rate of treatment in
both arms was low (14 % and 17 %) in our study. This
result is consistent with a previous nationwide survey
in Taiwan (13.7 %) [26]. Although the anticipated treat-
ment success rate is as high as 80 % in Taiwan, only
8.1 % of the population with HC achieved successful
treatment. The major treatment barriers included fear
of adverse effects, major disorders, ineligibility for in-
surance reimbursement, and lack of awareness of
therapy.
Comparing the hazard ratio of comorbidities between
TCM users and non-TCM users, the TCM users tended
to have a lower risk (0.4 − 0.6 times) of hepatic diseases,
suggesting a negative association of hepatitis B, liver cir-
rhosis, and alcoholic liver disease with TCM usage. One
possible explanation for this finding is that the use of
TCM might have a protective effect on liver diseases.
Another explanation is that patients with impaired liver
function would avoid herbal medications to prevent dis-
ease progression. The causal relationship warrants fur-
ther research in the future. However, thyroid diseases,
rheumatoid arthritis, osteoarthritis, and sicca syndrome
were extrahepatic syndromes that had higher incidence
rates in TCM users in Taiwan (Table 4). After adjusting
for time of visit, Charlson comorbidity index score, and
type of TCM service used, the hazard ratio of these co-
morbidities became less than 1 and was non-significant.
This means the TCM-seeking behaviour is associated
with extrahepatic diseases rather than hepatitis C. This
finding might be attributed to the side effects of
interferon-based antiviral therapy and the lack of satis-
faction with the current conventional therapies [27].
To date, the NHIRD has collected diagnosis data via
ICD-9-CM codes, which do not classify TCM
syndromes or diagnosis. However, TCM prescriptions
including formula or herbs are recorded in the NHIRD.
By analysing the prescription patterns, we could obtain
the possible TCM syndromes and indications for sub-
jects with HC (Table 5). In our database, the most com-
monly used formulas and single herbs for HC were
categorized into hepatic or extrahepatic based on their
therapeutic action and clinical indications. Jia-Wei-
Xiao-Yao-San, the most commonly used formula, has
demonstrated pleiotropic effects in patients with HC,
including anti-hepatic fibrosis [28], anti-hepatic cancer
[29], anti-depressant [30, 31], and anti-hyperthyroidism
effects [32]. However, it is unclear whether it has anti-
viral effects on HCV, and future investigations on this
subject are warranted. Dan-Shen (Salvia miltiorrhiza),
the most commonly used single herb, also has multiple
hepatoprotective and extrahepatic effects, such as anti-
hepatic fibrosis [33], anti-hepatic cancer [34, 35], anti-
diabetic [36], and lipid-lowering [37] effects, but no
apparent antiviral effects. Other commonly used pre-
scriptions had similar multi-target effects, which im-
plied that TCM physicians used these prescriptions to
prevent disease progression or to relieve relevant extra-
hepatic syndromes rather than to eradicate HCV.
The present study had some limitations. First, this
study did not include therapies that were not covered by
the NHI, such as newly antiviral agents or folk medi-
cines [38], which were purchased directly from TCM
herbal pharmacies. Consequently, the TCM utilization
rates might have been underestimated. However, because
only licensed TCM physicians can be reimbursed by the
NHI system, the quality of the diagnoses and treatments
in the NHIRD were ensured. Second, safety data in this
retrospective study are lacking, and thus we cannot
evaluate the safety of TCM. Third, our study only exam-
ined ambulatory visits to TCM or non-TCM clinics. Our
results for visits to Western medical clinics, including
inpatient services and emergency department visits, ba-
sically concurred with a previous study of outpatient
visits [39]. TCM inpatient services, which mostly in-
cluded hospital-based healthcare for senile populations,
were not that popular and therefore only represented a
small proportion of the TCM services received by HC
patients.
Conclusion
In summary, we conducted a nationwide, population-
based study on the use of TCM in patients with HC
based on one randomly selected cohort in 2010 from the
NHIRD healthcare claims data in Taiwan. It is that more
than 60 % of the TCM users were female and that the
utilization of TCM increased with age and peaked in the
age group of those 40 − 64 years old. Patients who had
more extrahepatic diseases and were taking more
Liu et al. BMC Complementary and Alternative Medicine  (2016) 16:397 Page 9 of 11
antiviral agents tended to visit TCM clinics. Jia-Wei-
Xiao-Yao-San and Dan-Shen (Salvia miltiorrhiza) were
the most commonly used formula and single herb, with
88,124 person-days and 59,252 person-days, respectively.
The high prevalence and distinct usage patterns of TCM
in the Taiwanese HC population warrant more substan-
tial, high-quality and/or well-designed clinical trials of
TCM use.
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